Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Jeffrey

Showing results (491-500 of 651) with videos related to

Pageof 66
Sort By:
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 23, 2014
Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profilesJerri M Rook, Mohammed N Tantawy, Mohammad S Ansari, et al.
Bioorganic & Medicinal Chemistry Letters|September 4, 2017
Discovery of a novel, CNS penetrant M<sub>4</sub> PAM chemotype based on a 6-fluoro-4-(piperidin-1-yl)quinoline-3-carbonitrile coreBlake R Bewley, Paul K Spearing, Rebecca L Weiner, et al.
Cancers|June 10, 2022
Expansion of Liver Transplantation Criteria for Hepatocellular Carcinoma from Milan to UCSF in Australia and New Zealand and Justification for Metroticket 2.0Savio G Barreto, Simone I Strasser, Geoffrey W McCaughan, et al.
Bioorganic & Medicinal Chemistry Letters|October 18, 2017
Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M<sub>4</sub> positive allosteric modulator (PAM) chemotype via scaffold hoppingMadeline F Long, Julie L Engers, Sichen Chang, et al.
Journal of Biomolecular Screening|April 17, 2015
Application of Parallel Multiparametric Cell-Based FLIPR Detection Assays for the Identification of Modulators of the Muscarinic Acetylcholine Receptor 4 (M4)Emery Smith, Peter Chase, Colleen M Niswender, et al.
Journal of Clinical and Translational Science|August 13, 2019
Come from away: Best practices in mini-sabbaticals for the development of young investigators: a White Paper by the SEQUIN (mini-Sabbatical Evaluation and QUality ImprovemeNt) GroupMichael H Pillinger, Stephenie C Lemon, Martin S Zand, et al.
JCI Insight|January 21, 2021
A GRM7 mutation associated with developmental delay reduces mGlu7 expression and produces neurological phenotypesNicole M Fisher, Aqeela AlHashim, Aditi B Buch, et al.
Journal of Medicinal Chemistry|August 23, 2014
Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380)Patrick R Gentry, Masaya Kokubo, Thomas M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|July 4, 2012
Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012Bruce J Melancon, Thomas J Utley, Christian Sevel, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2012
Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonismDouglas J Sheffler, Christian Sevel, Uyen Le, et al.
Pageof 66

Showing results (491-500 of 651) with videos related to

Sort By:
Pageof 66
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 23, 2014
Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profilesJerri M Rook, Mohammed N Tantawy, Mohammad S Ansari, et al.
Bioorganic & Medicinal Chemistry Letters|September 4, 2017
Discovery of a novel, CNS penetrant M<sub>4</sub> PAM chemotype based on a 6-fluoro-4-(piperidin-1-yl)quinoline-3-carbonitrile coreBlake R Bewley, Paul K Spearing, Rebecca L Weiner, et al.
Cancers|June 10, 2022
Expansion of Liver Transplantation Criteria for Hepatocellular Carcinoma from Milan to UCSF in Australia and New Zealand and Justification for Metroticket 2.0Savio G Barreto, Simone I Strasser, Geoffrey W McCaughan, et al.
Bioorganic & Medicinal Chemistry Letters|October 18, 2017
Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M<sub>4</sub> positive allosteric modulator (PAM) chemotype via scaffold hoppingMadeline F Long, Julie L Engers, Sichen Chang, et al.
Journal of Biomolecular Screening|April 17, 2015
Application of Parallel Multiparametric Cell-Based FLIPR Detection Assays for the Identification of Modulators of the Muscarinic Acetylcholine Receptor 4 (M4)Emery Smith, Peter Chase, Colleen M Niswender, et al.
Journal of Clinical and Translational Science|August 13, 2019
Come from away: Best practices in mini-sabbaticals for the development of young investigators: a White Paper by the SEQUIN (mini-Sabbatical Evaluation and QUality ImprovemeNt) GroupMichael H Pillinger, Stephenie C Lemon, Martin S Zand, et al.
JCI Insight|January 21, 2021
A GRM7 mutation associated with developmental delay reduces mGlu7 expression and produces neurological phenotypesNicole M Fisher, Aqeela AlHashim, Aditi B Buch, et al.
Journal of Medicinal Chemistry|August 23, 2014
Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380)Patrick R Gentry, Masaya Kokubo, Thomas M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|July 4, 2012
Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012Bruce J Melancon, Thomas J Utley, Christian Sevel, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2012
Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonismDouglas J Sheffler, Christian Sevel, Uyen Le, et al.
Pageof 66